From Bench to Breakthrough: The Evolution of Amanitin ADCs – Insights from HDP-101 Phase I/II & the Future of Payload Differentiation
- Differentiation through payloads: showcasing amanitin payloads and stressing the need for new ADC payload MoAs
- Exploring Phase I/II dose expansion data of HDP-101 and evaluating clinical performance against conjugates with validated payloads
- Reflecting on the development journey of HDP-101 to understand the hurdles to overcome with bringing a novel ADC payload to the clinic